Table 2 Multivariable analysis of factors associated with HR discordance.
Odds ratio | (95% CI) | p-value | |
|---|---|---|---|
Age at first diagnosis | |||
<50 years | 1.00 | ||
≥50 years | 1.11 | (0.77: 1.59) | 0.585 |
Time to MBC | |||
<6 months | 1.00 | ||
6–24 months | 0.84 | (0.35: 2.03) | 0.703 |
>24 months | 1.10 | (0.50: 2.40) | 0.814 |
Metastatic site | |||
Brain | 1.00 | ||
Visceral | 1.78 | (0.92: 3.44) | 0.087 |
Non-visceral | 1.38 | (0.63: 3.01) | 0.421 |
Bone only | 2.54 | (1.15: 5.63) | 0.022 |
Number of metastatic site | |||
<3 | 1.00 | ||
≥3 | 1.03 | (0.68: 1.56) | 0.884 |
MBC subtypes | |||
TNBC | 1.00 | ||
HR+/HER2− | 0.05 | (0.03: 0.08) | <0.001 |
HER2+ | 0.37 | (0.23: 0.59) | <0.001 |
Primary tumour treatments received | |||
Chemotherapy or target therapy | |||
No | 1.00 | ||
Yes | 0.98 | (0.63: 1.53) | 0.944 |
Hormonotherapy | |||
No | 1.00 | ||
Yes | 3.08 | (1.96: 4.82) | < 0.001 |
Year of diagnosis metastatic | |||
2007–2010 | 1 | ||
2011–2013 | 0.90 | (0.61: 1.33) | 0.605 |
2014 | 0.80 | (0.46: 1.41) | 0.447 |
